← Russell 3000 cross-section

OPK OPKO HEALTH, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-07-27, not restated
Healthcare

Scale

Market cap
$1.1bn
Revenue TTM
$588m
Net income TTM
$-73m
Free cash flow
$-134m
Composite score
43.0
Sector rank
#1956

Valuation

P / E
EV / EBITDA
20.2
EV / sales
1.4
FCF yield
-11.77%
Earnings yield vs 10-yr
-11.14pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-12.4%
EBITDA margin
7.0%
ROE
-6.2%
ROIC
-5.5%
Revenue growth
-11.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

RESULTS OF OPERATIONS Foreign Currency Exchange Rates Approximately 33.3% of our revenue for the six months ended June 30, 2026, was denominated in currencies other than the U.S. As of June 30, 2026, we held $6.8 million in open foreign exchange forward contracts related to inventory purchases on letters of credit, compared to $13.6 million in open contracts as of December 31, 2025. FOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025 Our consolidated income from operations for the three months ended June 30, 2026 and 2025 was as follows: Diagnostics Revenue. …OPKO HEALTH, INC., 10-Q, period ended 2026-06-30, filed 2026-07-27

Read the full passage →